Shionogi & Co., Ltd.
1-8, Doshomachi 3-Chome
89 articles with Shionogi & Co., Ltd.
U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment of Complicated Urinary Tract Infections
Shionogi & Co., Ltd. announced that the U.S. Food and Drug Administration’s Antimicrobial Drugs Advisory Committee voted to recommend approval of the investigational antibiotic cefiderocol for the treatment of complicated urinary tract infections, including pyelonephritis, in patients with limited or no alternative treatment options.
Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
Shionogi & Co., Ltd. announced that it has entered into a new license agreement with Hsiri Therapeutics, Inc. regarding a collaborative research and development program to discover and develop additional novel therapeutics for non-tuberculous mycobacterial diseases and tuberculosis.
Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens
APEKS-NP trial met primary endpoint of non-inferiority of cefiderocol compared to meropenem
Including Cefiderocol Phase III APEKS-NP Trial as Late-breaker Oral Presentation
ViiV Healthcare Announces Phase III Study Meets Primary Endpoint, Demonstrating the Ability to Control HIV-1 With the 2-drug Regimen Dovato in Virally Suppressed Patients Switching From a TAF-containing, 3-drug Regimen
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019)
ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
Shionogi to Present New Data at European Congress of Clinical Microbiology and Infectious Diseases 2019
Announced 12 data presentations taking place at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held April 13-16, 2019 in Amsterdam.
Shionogi to Present Clinical Data on Lusutrombopag at the International Liver Congress™ 2019 of the European Association for the Study of the Liver (EASL)
Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V., announced it will present four posters on lusutrombopag, a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at The International Liver Congress™, the annual meeting of the European Association for the Study of the Liver (EASL), to be held in Vienna, Austria, April 10-14, 2019.
PureTech’s Independent Affiliate Akili Announces Partnership with Shionogi to Develop and Commercialise Digital Therapeutics in Certain Asian Markets
Akili receives upfront payments totalling $20 million and has the potential to receive milestone payments for Japan and Taiwan commercialisation of up to an additional $105 million, in addition to substantial royalties on product sales
Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets
Akili to Create First-of-its-kind International Digital Medicine Development and Commercial Platform
Peptidream announced that it has entered into a multi-program collaborative research agreement with Osaka-based Shionogi & Co., Ltd for the discovery and development of a series of blood brain barrier (BBB) penetrating peptide drug-conjugates (PDCs).
Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commercialization
Deal Valued at Potential $160 Million plus Royalties, including $5 Million in Upfront Payments and $35 Million in Equity Investment
Shionogi to Present Clinical Data on Mulpleta® (lusutrombopag) at the Liver Meeting® 2018 of the American Association for the Study of Liver Diseases (AASLD)
Shionogi & Co., Ltd. (hereafter "Shionogi") announced it will present four posters on Mulpleta® (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at The Liver Meeting®, the premiere annual meeting in the science and practice of hepatology from the American Association for the Study of Liver Diseases (AASLD) to be held in San Francisco, November 9-13, 2018.
Shionogi & Co., Ltd. announced today that The Lancet Infectious Diseases journal has published clinical results from the pivotal randomized controlled trial evaluating cefiderocol for the treatment of complicated urinary tract infection (cUTI) in patients at risk of multidrug-resistant Gram-negative infections.
Today, the U.S. Food and Drug Administration approved Xofluza for the treatment of acute uncomplicated influenza in patients 12 years of age and older.
Shionogi & Co., Ltd. announced today that 14 presentations will feature the company’s investigational compounds at IDWeek™ 2018, in San Francisco, October 3-7, 2018.
Last year’s influenza season in the U.S. had record-breaking hospitalization rates. A lot of industry observers are looking at a new flu drug, baloxavir marboxil, for which clinical trial data was just published.
Baloxavir Marboxil Phase II and III Studies for the Treatment of Influenza Published in the New England Journal of Medicine
Shionogi & Co., Ltd. today announced the positive results from Phase II and III studies of baloxavir marboxil for the treatment of influenza in otherwise-healthy patients have been published in the New England Journal of Medicine (NEJM) in the September 6, 2018 issue.
As part of an earlier announced restructuring program, UK-based GlaxoSmithKline is laying off 650 staffers in the U.S. GlaxoSmithKline employees approximately 15,000 people in the U.S.
Shionogi Announces Upcoming Presentations from Symproic® (naldemedine) Studies at PAINWeek® 2018 Annual Conference
Shionogi & Co., Ltd. will present four scientific posters featuring pre-clinical and clinical findings of Symproic® (naldemedine) during the 12th Annual PAINWeek® Conference.